Botensilimab (AGEN1181)

Botensilimab · Agenus Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Botensilimab (AGEN1181), covering 2026-01-16 to 2026-01-16. Get the full timeline:

Most recent: Clinical Trial Update: A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma [Phase 2]